Actavis sees 2Q loss but Warner deal has reached final stages
This article was originally published in Scrip
Executive Summary
Generic drug developer Actavis has posted a second quarter loss of $4.27 per share, despite reporting a 47% increase in revenues, because of "restructuring costs." The Parsippany, New Jersey-based firm, previously known as Watson Pharmaceuticals, said the costs arose from the 2009 acquisition of UK drug maker Arrow. The combined assets were subsequently restructured from one global reporting unit into four new reporting units.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.